EUVIMEDEUVIMED entdecken
Crossref

Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System

Makiko Go, Yoshihiro Noguchi iD, Rikuto Masuda, Hiroki Asano, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura iD

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Makiko Go und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Japan. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Pyridines, Piperazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most common toxicities associated with cyclin‐dependent kinase (CDK) 4/6 inhibitor therapy include decreased leukopenia and neutropenia due to the inhibition of CDK6 of leukocyte and neutrophil precursors in bone marrow. These hematological toxicities are more commonly observed with palbociclib administration than with abemaciclib administration, which is approximately 13 times more selective against CDK4 than CDK6. Thus, even though both successfully inhibit CDK4/6, the side effects of palbociclib and abemaciclib differ due to differences in selectivity. Recent reports have suggested an association between palbociclib and medication‐related osteonecrosis of the jaw; however, reports on this association are inconsistent. This study investigated the potential association of palbociclib and abemaciclib with MRONJ using the FAERS. Signals of “Osteonecrosis of jaw” were detected only in females using palbociclib (cROR 025 : 2.08). Other signals detected included stomatitis‐related adverse events with abemaciclib and intraoral soft tissue damage and infection with palbociclib. As previous exploratory studies have reported MRONJ signals for bisphosphonates and denosumab, we calculated the aROR for palbociclib‐induced osteonecrosis of the jaw using concomitant bisphosphonates and denosumab as covariates. A signal was detected even after adjusting for sex, age, and concomitant medications as covariates (aROR0 025 : 5.74). A proper understanding of the differences in CDK selectivity is necessary for the appropriate use of CDK4/6 inhibitors. To the best of our knowledge, this is the first report on CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw. We believe that these results will offer new insights into adverse events related to the use of CDK4/6 inhibitors, and may aid in the proper use of CDK4/6 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6PyridinesPiperazinesProtein Kinase InhibitorsAminopyridinesBenzimidazolesHumansFemaleMaleUnited StatesAgedMiddle AgedOsteonecrosisUnited States Food and Drug AdministrationAdverse Drug Reaction Reporting SystemsAdultAged, 80 and overJaw Diseases

Stichwörter der Autor:innen

CDK4/6 inhibitorFAERSabemaciclibosteonecrosis of the jawpalbociclib

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPyridinesabemaciclibPiperazinesProtein Kinase InhibitorsCDK4 protein, humanAminopyridinesCDK6 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Japan.
  • Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan.
  • Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan.

ORCID-Profile: Yoshihiro Noguchi, Tomoaki Yoshimura

Förderung

  • Japan Society for the Promotion of Science KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Go, M., Noguchi, Y., Masuda, R., Asano, H., Kimura, M., Usami, E., & Yoshimura, T. (2024). Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System. International Journal of Cancer. https://doi.org/10.1002/ijc.34962

Vancouver

Go M, Noguchi Y, Masuda R, Asano H, Kimura M, Usami E, et al. Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System. International Journal of Cancer. 2024. doi:10.1002/ijc.34962

BibTeX
@article{Go2024,
  author = {Go, Makiko and Noguchi, Yoshihiro and Masuda, Rikuto and Asano, Hiroki and Kimura, Michio and Usami, Eiseki and Yoshimura, Tomoaki},
  title = {Association between CDK4/6 inhibitors and drug‐related osteonecrosis of the jaw: A pharmacoepidemiological study using the FDA Adverse Events Reporting System},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34962}
}
Kostenlos starten →